Discl	osures required under SEBI (Share Based Employee Be	nefits) Regulations, 2014
A	The Board of Directors in their report shall disclose any material change in the scheme(s) and whether the scheme(s) is / are in compliance with the regulations  Relevant disclosures in terms of the 'Guidance note on accounting for employee share-based payments' issued by ICAI or any other relevant accounting standards as prescribed from time to time	The Scheme is in compliance with the Regulations. Further, there has been no material change in the Scheme.  Deferred employee stock compensation cost for stock options is recognised as per the Guidance Note on Accounting for Employee Share-based Payments, issued by the
В	Diluted EPS on issue of shares pursuant to all the schemes covered under the regulations shall be disclosed in accordance with 'Accounting Standard 20 - Earnings Per Share' issued by ICAI or any other relevant accounting standards as prescribed from time to time	Institute of Chartered Accountants of India.  Diluted EPS for the financial year 2016-17: Re 0.14. The same is disclosed as per AS-20 of ICAI in the Accounts of the Company
С	Details related to ESOS	
(i)	A description of each ESOS that existed at any time during the year, including the general terms and conditions of each ESOS, including -  (a) Date of shareholders' approval	7 <sup>th</sup> September 2015
	(b) Total number of options approved under Equitas Employee Stock Option Scheme, 2015 (including outstanding options carried forward from earlier Equitas Employee Stock Option Scheme)	4,43,38,221
	(c) Vesting requirements	Options granted by the Company would vest with the employee subject to the employee continuing in the employment of the Company and compliance with the terms of Equitas ESOS, 2015 as laid down by the Nomination, Remuneration and Governance Committee.  The vesting shall commence any time after the expiry of one year from the date of the grant of the Options to the eligible employee and could extend up to six years from the date of the grant of the Options. The Options could vest in tranches.

	(d) Exercise price or pricing formula  (e) Maximum term of options granted	The Nomination, Remuneration & Governance Committee approves the grant of options to eligible employees from time to time. The grant price will be based on the closing price of the stock on the previous day, in the Stock Exchange where the volume of trade has been the highest.  The vesting can extend upto six years from the date of grant of
	(f) Source of shares (primary, secondary or combination)	options.  Primary
	(g) Variation in terms of options	Nil
(ii)	Method used to account for ESOS - Intrinsic or fair value.	Intrinsic value.
(iii)	Where the company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the company shall also be disclosed.	The impact on the difference in profits during the financial year 2016-17: The Profits will be lower by ₹ 2,950.09 lakhs. The impact on the EPS during the financial year 2016-17 is ₹(0.89).  The above have been disclosed in the Notes to accounts of the Company.
(Iv)	Option movement during the year (For each ESOS):	Refer Annexure - 1
(v)	Weighted-average exercise prices and weighted-average fair values of options shall be disclosed separately for options whose exercise price either equals or exceeds or is less than the market price of the stock.	Weighted average exercise price and weighted average fair value of options are ₹ 175.33 per share and ₹ 174.87 per share respectively. The weighted average exercise price is higher than the market price of the shares.
(vi)	Employee wise details (name of employee, designation, number of options granted during the year, exercise price) of options granted to - (a) senior managerial personnel; (b) any other employee who receives a grant in any one year of option amounting to 5% or more of option granted during that year; and (c) identified employees who were granted option, during any one year, equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the company at the time of grant.	<ul> <li>(a) 27,000 options were granted during the year to Mr Bhaskar S, ED &amp; CEO at an exercise price of ₹184.</li> <li>(b) Nil</li> <li>(c) - Nil</li> </ul>

(vii)	A description of the method and significant assumptions used during the year to estimate the fair value of options including the following information  (a) the weighted-average values of share price, exercise price, expected volatility, expected option life, expected dividends, the risk-free interest rate and any other inputs to the model;  (b) the method used and the assumptions made to incorporate the effects of expected early exercise;  (c) how expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility; and  (d) whether and how any other features of the option grant were incorporated into the measurement of fair value, such as a market condition.	Disclosed in Annexure 2. (Please refer Notes to Accounts 3.6 (b) Employee Stock Option Scheme, of Annual Accounts of the Company).					
	Disclosures in respect of grants made in three years						
/:\	prior to IPO under each ESOS	Disclosed in American					
(i)	Until all options granted in the three years prior to the IPO have been exercised or have lapsed, disclosures of the information specified above in respect of such options shall also be made.	Disclosed in Annexure 2. (Please refer Notes to Accounts 3.6 (a) Employee Stock Option Scheme, of Annual Accounts of the Company).					
D	Details related to ESPS	Not applicable					
(i)	The following details on each ESPS under which allotments were made during the year:  (a)Date of shareholders' approval (b)Number of shares issued (c)The price at which such shares are issued (d)Lock-in period  The following details regarding allotment made						
(")	under each ESPS, as at the end of the year						
	Particulars	Details					
	The details of the number of shares issued under ESPS	Not applicable					
	The price at which such shares are issued						
	Employee-wise details of the shares issued to;						
	(i) senior managerial personnel;						
	(ii) any other employee who is issued shares in any one year amounting to 5% or more shares issued during that year;						
	(iii) identified employees who were issued shares during any one year equal to or exceeding 1% of the issued capital of the company at the time of issuance;						

	T	
	Consideration received against the issuance of	
	shares, if scheme is implemented directly by the	
	company	
	Loan repaid by the Trust during the year from	
	exercise price received	
E	Details related to SAR	Not applicable
(i)	A description of each SAR scheme that existed at	
(.,	any time during the year, including the general	
	terms and conditions of each SAR scheme, including	
	terms and conditions of each SAN scheme, including	
	- (a)Data of charabaldors' annual	
	(a)Date of shareholders' approval	
	(b) Total number of shares approved under the SAR	
	scheme	
	(c)Vesting requirements	
	(d)SAR price or pricing formula	
	(e)Maximum term of SAR granted	
	(f) Method of settlement (whether in cash or equity)	
	(g) Choice of settlement (with the company or the	
	employee or combination)	
	(h)Source of shares (primary, secondary or	
	combination)	
	(i) Variation in terms of scheme	
(ii)	Method used to account for SAR - Intrinsic or fair	
` '	value.	
(iii)	Where the company opts for expensing of SAR using	
, ,	the intrinsic value of SAR, the difference between	
	the employee compensation cost so computed and	
	the employee compensation cost that shall have	
	been recognized if it had used the fair value of SAR,	
	shall be disclosed. The impact of this difference on	
	profits and on EPS of the company shall also be	
	disclosed.	
(iv)	SAR movement during the year (For each SAR	
(10)	scheme):	
	Particulars	Details
	Number of SARs outstanding at the beginning of the	Not applicable
	Number of CARs granted during the year	
	Number of SARs granted during the year	
	Number of SARs forfeited / lapsed during the year	
	Number of SARs vested during the year	
	Number of SARs exercised / settled during the year	
	Number of SARs outstanding at the end of the year	
	Number of SARs exercisable at the end of the year	
(v)	Employee-wise details (name of employee,	
	designation, number of SAR granted during the year,	
	exercise price) of SAR granted to -	
	(a) senior managerial personnel;	
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	I .

	(b) any other employee who receives a grant in any	
	one year of amounting to 5% or more of SAR granted	
	during that year; and	
	(c) identified employees who were granted SAR,	
	during any one year, equal to or exceeding 1% of the	
	issued capital (excluding outstanding warrants and	
	conversions) of the company at the time of grant.	
	the second secon	
	Disclosures in respect of grants made in three years	
	prior to IPO under each SAR scheme	
(i)	Until all SARs granted in the three years prior to the	Not applicable
۱٠/	IPO have been exercised or have lapsed, disclosures	Troc applicable
	of the information specified above in respect of such	
	SARs shall also be made	
F	Details related to GEBS / RBS	
	A description of each GEBS / RBS scheme that	Not Applicable
(i)	,	Not Applicable
	existed at any time during the year, including the	
	general terms and conditions of each such scheme,	
	including-	
	(a)Date of shareholders' approval	
	(b)Kind of benefits to be granted under the scheme	
	(c)Beneficiaries of the scheme	
	(d)Total assets of the scheme	
	(e) Quantum of holding in own shares / listed	
	holding company shares (both absolute and in	
	percentage)	
	(f) Whether scheme is in compliance of regulation	
	26(2)/27(3) of the regulations, as applicable	
	(g) Variation in terms of scheme	
G	Details related to Trust	
	The following details, inter alia, in connection with	Not Applicable
	transactions made by the Trust meant for the	
	purpose of administering the schemes under the	
	regulations are to be disclosed	
403		
(i)	General information on all schemes	D . "
S.	Particulars	Details
No.	Name of the Trust	Not Applicable
2		Not Applicable
	Details of the Trustee(s)	
3	Amount of loan disbursed by company / any	
_	company in the group, during the year	
4	Amount of loan outstanding (repayable to company	
	/ any company in the group) as at the end of the	
	year	
5	Amount of loan, if any, taken from any other source	
	for which company / any company in the group has	

	provided any security or guarantee	
6	Any other contribution made to the Trust during the year	
(ii)	Brief details of transactions in shares by the Trust	
(,	(a) Number of shares held at the beginning of the year;	Not Applicable
	(b) Number of shares acquired during the year through (i) primary issuance (ii) secondary acquisition, also as a percentage of paid up equity capital as at the end of the previous financial year, along with information on weighted average cost of acquisition per share;  (c) Number of shares transferred to the employees /	
	sold along with the purpose thereof;	
	(d) Number of shares held at the end of the year	
(iii)	In case of secondary acquisition of shares by the Trust	
	Number of shares	As a percentage of paid-up equity capital as at the end of the year immediately preceding the year in which shareholders' approval was obtained
	Held at the beginning of the year	Not Applicable
	Acquired during the year	
	Sold during the year	
	Transferred to the employees during the year	
	Held at the end of the year	

For and on behalf of the Board of Directors

Chennai Bhaskar S
May 5, 2017 Executive Dir

Bhaskar S Rangachary N Executive Director & CEO Chairman

# Annexure – 1

Particulars	Total
Number of options outstanding at the beginning of the period	4,33,55,425
Number of options granted during the year	1,93,85,700
Number of options forfeited / lapsed during the year	55,66,843
Number of options vested during the year	28,96,582
Number of options exercised during the year	24,38,834
Number of shares arising as a result of exercise of options	24,38,834
Money realized by exercise of options (INR), if scheme is implemented directly by the company	₹1051.96 lakh
Loan repaid by the Trust during the year from exercise price received	-
Number of options outstanding at the end of the year	4,09,16,591
Number of options exercisable at the end of the year	36,58,555

For and on behalf of the Board of Directors

Chennai May 5, 2017 Bhaskar S
Executive Director & CEO

Rangachary N Chairman

# Annexure 2

#### **Equitas Holdings Limited**

Notes forming part of the financial statements for the year ended 31 March 2017

#### 3.6 Employee Stock Option Scheme

(a) On 17 December 2007, the Company established an Employees Stock Option Scheme 2007 (ESOP Scheme 2007). Under the plan, the Company is authorized to issue upto 5,620,000 Equity Shares of ₹ 10 each to eligible employees of the Company and its Subsidiaries. Employees covered by the plan are granted an option to purchase shares of the Company subject to the requirements of vesting. A Remuneration and Nomination Committee constituted by the Board of Directors of the Company administers the plan.

During the year ended 31 March 2013, the Company established a new employee stock option scheme titled Equitas Employees Stock Option Scheme, 2012 (ESOP Scheme 2012) effective from 10 November 2012. Under the plan, the Company was authorized to issue upto 1,000,000 Equity Shares of ₹ 10 each to eligible employees of the Company and its Subsidiaries. Further, the outstanding options under the ESOP Scheme 2007 has been transferred and made available for grant under the new scheme.

During the year ended 31 March 2014, the Company established a new employee stock option scheme titled Equitas Employees Stock Option Scheme, 2014 (ESOP Scheme 2014) effective from 18 July 2014. Under the plan, the Company was authorized to issue upto 10,500,000 Equity Shares of ₹ 10 each to eligible employees of the Company and its Subsidiaries. Further, the outstanding options under the ESOP Scheme 2012 has been transferred and made available for grant under the new scheme.

During the previous year ended 31 March 2015, pursuant to the issue of bonus shares for the existing shareholders, the Company granted 2 additional options for every 1 option outstanding to be exercised as on the date of bonus issue. Further, the exercise price for each option was been reduced to one-third of the original exercise price determined at the grant date.

During the previous year ended 31 March 2016, the Company established a new employee stock option scheme titled Equitas Employees Stock Option Scheme, 2015 (ESOP Scheme 2015) effective from 7 September 2015. Under the plan, the Company was authorized to issue upto 22,200,000 Equity Shares of ₹ 10 each to eligible employees of the Company and its Subsidiaries. Further, the outstanding options under the ESOP Scheme 2014 has been transferred and made available for grant under the new scheme.

As at 31 March 2017, 26,777,878 (As at 31 March 2016 - 15,397,855) (net of forfeitures) options were outstanding, which were granted at various exercise prices. The following are the outstanding options as at 31 March 2017:

Particulars	Grant 1	Grant 2	Grant 3	Grant 4	Grant5	Grant 6	Grant 7	Grant 8	Grant 9	Grant 10	Grant 11	Grant 12
Date of Grant	26-Feb-08	9-Jun-08	1-Nov-08	22-Apr-09	28-Oct-09	26-Apr-10	27-Oct-10	13-May-11	2-Nov-11	9-May-12	7-Nov-12	4-May-13
Exercise Price Per Option (₹) post bonus options	10.00*	12.00*	10.67	12.00	26.67	33.34	40.00	40.00	40.00	40.00	40.00	40.00
Total Options granted and outstanding as at 1 April 2016	-	-	-	51,258	49,788	229,371	316,731	243,052	208,682	331,211	397,925	265,466
Options granted during the Period	-	-	-	-	-	-	-	-	-	-	-	-
Less: Options Forfeited / Lapsed	-	-	-	1,500	13,080	24,084	53,811	21,755	21,982	42,060	75,937	45,355
Options Exercised	-	-	-	49,758	36,708	154,149	208,881	162,764	133,288	186,122	180,618	70,524
Options Outstanding as at 31 March 2017	-	-	-	-	-	51,138	54,039	58,533	53,412	103,029	141,370	149,587
vested	-	-	-	-	-	51,138	54,039	58,533	53,412	103,029	141,370	101,347
yet to vest	-	-	-	-	-	-	=	-	-	-	-	48,240

# Notes forming part of the financial statements for the year ended 31 March 2017

Particulars	Grant 13	Grant 14	Grant 15	Grant 16	Grant 17	Grant 18	Grant 19	Grant 20	Grant 21	Grant 22	Grant 23	Grant 24
Date of Grant	15-Nov-13	9-May-14	12-Nov-14	7-May-15	7-Aug-15	6-Nov-15	1-Jul-16	4-Jul-16	5-Aug-16	10-Sep-16	21-Oct-16	1-Feb-17
Exercise Price Per Option (Rs) post bonus options	40.00	43.34	55.00	65.00	70.00	70.00	178.00	184.00	173.00	182.00	183.00	165.00
Total Options granted and outstanding as at 1	1,262,734	1,693,758	2,511,379	1,727,350	2,184,700	3,924,450	-	-	-	-	-	-
Options granted during the period	-	-	-	-	-	-	7,597,900	838,500	1,840,150	2,007,200	2,038,500	5,063,450
Less: Options Forfeited / Lapsed	171,693	352,237	573,290	432,114	381,741	951,904	1,158,850	-	291,500	311,200	315,100	327,650
Options Exercised	453,529	317,619	306,877	90,465	27,596	59,936	-	-	-	-	-	-
Options Outstanding as at 31 March 2017	637,512	1,023,902	1,631,212	1,204,771	1,775,363	2,912,610	6,439,050	838,500	1,548,650	1,696,000	1,723,400	4,735,800
vested	398,924	453,242	795,112	262,921	464,053	721,435	-	-		-	-	-
yet to vest	238,588	570,660	836,100	941,850	1,311,310	2,191,175	6,439,050	838,500	1,548,650	1,696,000	1,723,400	4,735,800

<sup>\*</sup>The exercise price is before bonus issue.

### Notes forming part of the financial statements for the year ended 31 March 2017

(b) The fair value of options used to compute Proforma net profit and earnings per Equity Share have been estimated on the date of the grant, using Black-Scholes model by an external firm of Chartered Accountants.

The key assumptions used in Black-Scholes model for calculating fair value as on the date of the grant are:

Grant 1	Grant 2	Grant 3	Grant 4	Grant5	Grant 6	Grant 7	Grant 8	Grant 9	Grant 10	Grant 11	Grant 12
					Date o	of Grant					
26-Feb-08	9-Jun-08	1-Nov-08	22-Apr-09	28-Oct-09	26-Apr-10	27-Oct-10	13-May-11	2-Nov-11	9-May-12	7-Nov-12	4-May-13
8.50%	8.75% to 9%	9.75%	8.25%	6.75% to 7%	6.50% to 7.25%	7.25% to 7.50%	7.9% to 8.05%	8.40% to 8.65%	8.01% to 8.25%	7.89% to 8%	7.12% to 7.23%
3.33 to 5.33	3.33 to 5.33	3.33 to 5.33	3.33 to 5.33	3.33 to 5.33	3.33 to 5.33	3.33 to 5.33	2.58 to 5.58	2.58 to 5.58	2.58 to 5.58	2.67 to 5.67	2.67 to 5.67
yrs	yrs	yrs	yrs	yrs	yrs	yrs	yrs	yrs	yrs	yrs	yrs
43% to 45%	43% to 45%	41% to 47%	42% to 44%	37% to 44%	37% to 40%	35% to 40%	38% to 41%	38% to 40%	39% to 42%	38% to 42%	33% to 37%
0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
10.00	12.00	10.67	12.00	26.67	33.34	40.00	40.00	40.00	40.00	40.00	40.00
0.63			2.75	2.08	6.75	8.70		9.34	3.28	3.87	2.92
0.81	3.91	5.07	3.18	2.56	8.34	10.83	11.66	12.20	4.41	4.84	5.07
1.00	4.02	5.76	3.85	3.78	10.09	13.06	13.79	14.26	6.00	6.65	6.31
1.32	4.70	6.12	4.56	5.38	12.27	15.84	16.11	16.19	7.25	7.97	7.99
	26-Feb-08 8.50% 3.33 to 5.33 yrs 43% to 45% 0% 10.00 0.63 0.81 1.00	26-Feb-08 9-Jun-08 8.50% 8.75% to 9% 3.33 to 5.33 yrs 7yrs 43% to 45% 0%  10.00 12.00  0.63 3.14 0.81 3.91 1.00 4.02	26-Feb-08         9-Jun-08         1-Nov-08           8.50%         8.75% to 9%         9.75%           3.33 to 5.33 yrs         3.33 to 5.33 yrs         3.33 to 5.33 yrs           43% to 45%         41% to 47%           0%         0%           10.00         12.00         10.67           0.63         3.14         4.06           0.81         3.91         5.07           1.00         4.02         5.76	26-Feb-08         9-Jun-08         1-Nov-08         22-Apr-09           8.50%         8.75% to 9%         9.75%         8.25%           3.33 to 5.33 yrs         3.33 to 5.33 yrs         3.33 to 5.33 yrs         3.33 to 5.33 yrs           43% to 45%         41% to 47%         42% to 44%           0%         0%         0%           10.00         12.00         10.67         12.00           0.63         3.14         4.06         2.75           0.81         3.91         5.07         3.18           1.00         4.02         5.76         3.85	26-Feb-08         9-Jun-08         1-Nov-08         22-Apr-09         28-Oct-09           8.50%         8.75% to 9%         9.75%         8.25%         6.75% to 7%           3.33 to 5.33 yrs         3.7% to 44%           43% to 45%         41% to 47%         42% to 44%         37% to 44%           0%         0%         0%         0%         0%           10.00         12.00         10.67         12.00         26.67           0.63         3.14         4.06         2.75         2.08           0.81         3.91         5.07         3.18         2.56           1.00         4.02         5.76         3.85         3.78	26-Feb-08         9-Jun-08         1-Nov-08         22-Apr-09         28-Oct-09         26-Apr-10           8.50%         8.75% to 9%         9.75%         8.25%         6.75% to 7%         6.50% to 7.25%           3.33 to 5.33 yrs         3.7% to 44%         37% to 40%           0%         0%         0%         0%         0%         0%         0%           10.00         12.00         10.67         12.00         26.67         33.34           0.63         3.14 0.06         2.75 0.81 3.18 2.56 8.34 1.00         8.34 1.00         4.02 5.76 3.85 3.78 10.09	Table   Tabl	26-Feb-08         9-Jun-08         1-Nov-08         22-Apr-09         28-Oct-09         26-Apr-10         27-Oct-10         13-May-11           8.50%         8.75% to 9%         9.75%         8.25%         6.75% to 7%         6.50% to 7.25%         7.25% to 7.50%         8.05%           3.33 to 5.33 yrs         3.35 to 5.33 yrs         3.35 to 5.33 yrs         3.37% to 40%         35% to 40%         38% to 41%           0% </td <td>26-Feb-08         9-Jun-08         1-Nov-08         22-Apr-09         28-Oct-09         26-Apr-10         27-Oct-10         13-May-11         2-Nov-11           8.50%         8.75% to 9%         9.75%         8.25%         6.75% to 7%         6.50% to 7.25%         7.25% to 7.50%         7.9% to 8.05%         8.65%           3.33 to 5.33 yrs         3.5% to 40% 35% to 40% 35% to 40% 35% to 40% 0%         38% to 41% 38% to 40% 0%           0%</td> <td>  26-Feb-08   9-Jun-08   1-Nov-08   22-Apr-09   28-Oct-09   26-Apr-10   27-Oct-10   13-May-11   2-Nov-11   9-May-12     8.50%   8.75% to 9%   9.75%   8.25%   6.75% to 7%   6.50% to 7%   7.25% to 7.50%   7.50%   8.05%   8.05%   8.65%   8.25%     3.33 to 5.33   yrs   y</td> <td>  26-Feb-08   9-Jun-08   1-Nov-08   22-Apr-09   28-Oct-09   26-Apr-10   27-Oct-10   13-May-11   2-Nov-11   9-May-12   7-Nov-12     8.50%   8.75% to 9%   9.75%   8.25%   6.75% to 7%   7.25%   7.25%   7.55%   7.55%   8.05%   8.65%   8.25%   8.25%   7.89% to 8%     3.33 to 5.33   yrs   y</td>	26-Feb-08         9-Jun-08         1-Nov-08         22-Apr-09         28-Oct-09         26-Apr-10         27-Oct-10         13-May-11         2-Nov-11           8.50%         8.75% to 9%         9.75%         8.25%         6.75% to 7%         6.50% to 7.25%         7.25% to 7.50%         7.9% to 8.05%         8.65%           3.33 to 5.33 yrs         3.5% to 40% 35% to 40% 35% to 40% 35% to 40% 0%         38% to 41% 38% to 40% 0%           0%	26-Feb-08   9-Jun-08   1-Nov-08   22-Apr-09   28-Oct-09   26-Apr-10   27-Oct-10   13-May-11   2-Nov-11   9-May-12     8.50%   8.75% to 9%   9.75%   8.25%   6.75% to 7%   6.50% to 7%   7.25% to 7.50%   7.50%   8.05%   8.05%   8.65%   8.25%     3.33 to 5.33   yrs   y	26-Feb-08   9-Jun-08   1-Nov-08   22-Apr-09   28-Oct-09   26-Apr-10   27-Oct-10   13-May-11   2-Nov-11   9-May-12   7-Nov-12     8.50%   8.75% to 9%   9.75%   8.25%   6.75% to 7%   7.25%   7.25%   7.55%   7.55%   8.05%   8.65%   8.25%   8.25%   7.89% to 8%     3.33 to 5.33   yrs   y

## Notes forming part of the financial statements for the year ended 31 March 2017

	Grant 13	Grant 14	Grant 15	Grant 16	Grant 17	Grant 18	Grant 19	Grant 20	Grant 21	Grant 22	Grant 23	Grant 24			
Variables		Date of grant													
	15-Nov-13	9-May-14	12-Nov-14	7-May-15	7-Aug-15	6-Nov-15	1-Jul-16	4-Jul-16	5-Aug-16	10-Sep-16	21-Oct-16	1-Feb-17			
Risk Free Interest Rate	8.50% to 8.68%	8.38% to 8.60%	8.50% to 8.68%	7.74% to 7.79%	7.69% to 7.89%	7.43% to 7.64%	7.03% to 7.34%	7.03% to 7.32%	6.78% to 7.04%	6.71% to 6.91%	6.70% to 7.00%	6.45% to 6.84%			
Expected Life	2.64 to 5.67 yrs	2.64 to 5.67 yrs	2.64 to 5.67 yrs	2.67 to 5.67 yrs	2.67 to 5.67 yrs	2.67 to 5.67 yrs	2.50 to 5.50 yrs	2.58 to 5.58 yrs	2.58 to 5.58 yrs	2.58 to 5.58 yrs	2.50 to 5.50 yrs	2.58 to 5.58 yrs			
Expected Volatility	34% to 39%	33% to 38%	35% to 39%	33% to 37%	36% to 39%	33.80% to 37%	23.60% to 26%	23.40% to 26%	22.80% to 26%	22% to 25%	23.10% to 39.20%	22.20% to 24.70 %			
Dividend Yield	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%			
Price of the underlying Share at the time of the Option Grant (₹) after adjustment of bonus options	40.00	43.34	55.00	65.00	70.00	70.00	177.70	183.75	172.10	181.75	182.50	164.35			
Fair Value of the Option (₹)  1 <sup>st</sup> Stage  2 <sup>nd</sup> Stage	4.34 7.08	8.56 11.59	7.80 11.66			16.00 18.79	40.66 53.39	42.76 55.99		40.22 53.26	40.45 52.49				
3 <sup>rd</sup> Stage 4 <sup>th</sup> Stage	8.53 9.93	13.38 15.68	14.41	18.40	25.33	23.55	61.83 70.45	64.60	59.26	62.47 70.88	61.08 87.23	55.01			

## Notes forming part of the financial statements for the year ended 31 March 2017

(c) Had compensation cost for the stock options granted under the Scheme been determined based on the fair value approach, the Company's net profit / (loss) and earnings per share would have been as per the Proforma amounts indicated below:

Particulars	For the year ended 31 March 2017 ₹ in lakh	For the year ended 31 March 2016 ₹ in lakh
Net Profit as per Statement of Profit and Loss (as reported) Add: Stock Based Employee Compensation Expense included in profit before tax	468.17	211.63
Less: Stock Based Compensation Expense Determined under Fair Value based Method (Proforma)	2,950.09	487.28
Net (Loss) (Proforma)	(2,481.92)	(275.65)
Particulars	For the year ended 31 March 2017	For the year ended 31 March 2016
Basic Earnings per Share of ₹ 10 each (as reported) Basic Earnings per Share of ₹ 10 each (Proforma) Diluted Earnings per Share of ₹ 10 each (as reported)	0.14 (0.75) 0.14	0.08 (0.10) 0.08

For and on behalf of the Board of Directors

Bhaskar S Executive Director & CEO Rangachary N Chairman (0.73)

(0.10)

Chennai 05-May-17

Diluted Earnings per Share of ₹ 10 each (Proforma)